Sequential therapy versus triple therapy for the first line treatment of helicobacter pylori in korea: A nationwide randomized trial

Gut and Liver

Volumn 10, Issue 4, 2016, Pages 556-561

  Kim, Joon Sung ^a   Kim, Byung Wook ^a   Hong, Su Jin ^b   Kim, Jin Il ^c   Shim, Ki Nam ^d   Kim, Jie Hyun ^e   Baik, Gwang Ho ^f   Kim, Sang Wook ^g   Song, Hyun Joo ^h   Kim, Ji Hyun ⁱ  

^a The Catholic University of Korea   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Hallym University College of Medicine   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h Jeju National University School of Medicine   (South Korea)

ⁱ Inje University College of Medicine   (South Korea)

Author keywords

Disease eradication; Drug resistance; Helicobacter pylori

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; PANTOPRAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG THERAPY; EPIGASTRIC DISCOMFORT; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL DRUG THERAPY; SIDE EFFECT; SOUTH KOREA; TRIPLE DRUG THERAPY; WEAKNESS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 84978512282     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15470     Document Type: Article

References (36)

1. Blaser MJ. Helicobacter pylori and gastric diseases. BMJ 1998;316: 1507-1510.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
3. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a metaanalysis. Digestion 2011;83:253-260.
4. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and antihelicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888.
5. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a stateof-the-art critique. Am J Gastroenterol 2005;100:2100-2115.
6. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973.
7. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825.
8. Coelho LG, León-Barúa R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection: Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000;95:2688-1691.
9. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
10. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
11. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-1268.
12. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153.
13. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340.
14. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3-26.
15. Gong EJ, Yun SC, Jung HY, et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci 2014;29:704-713.
16. Heo J, Jeon SW. Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2014;63:141-145.
17. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-726.
18. Kim JS, Ji JS, Choi H, Kim JH. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2014;38:118-125.
19. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-3079
20. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-931.
21. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a metaanalysis. J Clin Pharm Ther 2009;34:41-53.
22. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206-214.
23. Kim JS, Kim BW, Ham JH, et al. Sequential therapy for Helicobacter pylori infection in Korea: systematic review and metaanalysis. Gut Liver 2013;7:546-551.
24. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-186.e3.
25. An B, Moon BS, Kim H, et al. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann Lab Med 2013;33:415-419.
26. Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014;109:1595-1602.
27. Gisbert JP, Pérez-Aisa A, Bermejo F, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013;47:130-135.
28. Gisbert JP, Bermejo F, Castro-Fernández M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008;103:71-76.
29. Manfredi M, Bizzarri B, de'Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012;17:246-253.
30. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;19: 131-134.
31. Kang KK, Lee DH, Oh DH, et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014;20:6932-6938.
32. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21-28.
33. Graham DY, Fischbach LA. Letter: the ethics of using inferior regimens in H. pylori randomised trials. Aliment Pharmacol Ther 2012;35:852-854.
34. Yoon K, Kim N, Nam RH, et al. Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea. J Gastroenterol Hepatol 2015;30:490-495.
35. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and metaanalysis of sequential therapy. BMJ 2013;347:f4587.
36. Keum B, Lee SW, Kim SY, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole. Korean J Gastroenterol 2005;46:433-439.